1. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Issue 2 (16th November 2016) Authors: Ungar, B.; Kopylov, U.; Engel, T.; Yavzori, M.; Fudim, E.; Picard, O.; Lang, A.; Williet, N.; Paul, S.; Chowers, Y.; Bar‐Gil Shitrit, A.; Eliakim, R.; Ben‐Horin, S.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 2(2017) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Issue 12 (19th April 2016) Authors: Ungar, B.; Mazor, Y.; Weisshof, R.; Yanai, H.; Ron, Y.; Goren, I.; Waizbard, A.; Yavzori, M.; Fudim, E.; Picard, O.; Loebstein, R.; Kopylov, U.; Dotan, I.; Chowers, Y.; Eliakim, R.; Ben‐Horin, S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 43:Issue 12(2016) Page Start: 1293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗